Jane Street’s Tarsus Pharmaceuticals TARS Stock Holding History

Jane Street’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.5M	Buy	192,000 +7,700	+4%	+$538K	﹤0.01%	2179
2025 Q4	$15.1M	Buy	+184,300	New	+$13.8M	﹤0.01%	1862
2025 Q1	–	Sell	-29,800	Closed	-$1.65M	–	10579
2024 Q4	$1.65M	Sell	29,800 -11,900	-29%	-$540K	﹤0.01%	4460
2024 Q3	$1.37M	Buy	41,700 +23,300	+127%	+$655K	﹤0.01%	5238
2024 Q2	$500K	Buy	+18,400	New	+$619K	﹤0.01%	7028

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jane Street's TARS Position: Q1 2026 in Review

Jane Street sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 20,486 shares — an estimated $1.43M sold.

Jane Street first reported a position in TARS in Q3 2023 and held it in 9 quarters. The position peaked at $3.6M in Q3 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

Jane Street reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Jane Street sold 20,486 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $1.43M.
Jane Street first reported a position in Tarsus Pharmaceuticals in Q3 2023 and held it in 9 quarters.
Jane Street's Tarsus Pharmaceuticals position peaked at $3.6M in Q3 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.